NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDsโ Attention on Second-Generation Symphony Suite for Recurrence Risk and Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 23, 2013 โ Agendiaโs innovations in genomic testing Read More
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 โ New breast cancer research incorporating ย the SymphonyTM suite Read More
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, September 9, 2013 โ Agendia, a leader in molecular cancer diagnostics, today announced that multiple established Read More